Recently, on September 4, 2026, the U.S. Attorney’s Office for the District of Massachusetts announced that a Massachusetts med spa owner had been sentenced to nearly 4 years in prison after performing thousands of cosmetic procedures using counterfeit Botox and dermal fillers imported from China and Brazil.

The defendant was not licensed to perform injections and falsely represented herself as a nurse, receiveing more than $1M in payments from her 900 plus clients.

The case is a striking example of what can happen when pharmaceutical products move outside legitimate, regulated channels.

Counterfeit drugs aren’t just a supply-chain problem, they can put patients at serious risk.

More Than 2,700 Procedures Performed using Counterfeit Products

According to the U.S. Attorney’s Office, Rebecca Fadanelli – the unlicensed med spa owner falsely represented counterfeit products as authentic Botox and FDA-approved dermal fillers to clients.

Authorities found counterfeit versions of Botox, Sculptra, Restylane, and Juvéderm being used at the med spa, many of which had been imported from China and Brazil. They also found bacteriostatic water used to dilute Botox that tested positive for bacteria capable of causing infection.

The scale of the operation:

2,700+ injection procedures performed
900+ clients received procedures
$1M+ collected from clients

Fadanelli ultimately pleaded guilty to four counts of importing merchandise contrary to law, two counts of selling or dispensing a counterfeit drug, and two counts of selling or dispensing a counterfeit device.

The consequences were significant: 46 months in federal prison, followed by two years of supervised release, plus more than $1 million each in restitution and forfeiture.

What Happened to Patients?

The most concerning part of the case is what happened to patients.

The Justice Department reported that numerous clients experienced adverse health effects, including infections, facial or eye drooping and paralysis, double vision, impaired eyesight, severe swelling, and hard lumps or nodules. Multiple clients required hospitalization or additional medical treatment.

During searches of the med spa locations, authorities also recovered products labeled as well-known injectable brands that manufacturers subsequently identified as counterfeit. Laboratory testing of bacteriostatic water recovered during the investigation found bacteria capable of causing infection.

The case demonstrates that counterfeit pharmaceuticals aren’t merely a paperwork or regulatory issues. When the legitimacy and source of a product cannot be trusted, patient safety can be directly affected.

Knowing Where a Drug Came From Matters

For pharmacies, the case reinforces a fundamental principle of pharmaceutical supply-chain security:

Know your product. Know your source. Know your trading partners.

The government did not describe this case as a DSCSA enforcement action. It involved counterfeit drugs and devices, unlawful importation, unlicensed administration, and other criminal conduct. That distinction is important.

But the underlying risks demonstrate why pharmaceutical traceability and supply-chain controls matter.

When prescription drugs move through the legitimate U.S. pharmaceutical supply chain, pharmacies need processes that provide visibility into where products originated, who supplied them, and whether required documentation accompanies them.

That is precisely where the broader objectives of the Drug Supply Chain Security Act (DSCSA) become relevant.

Enforcement is Already Happening

The Massachusetts case is an extreme example involving deliberate criminal conduct, but its broader lesson for the pharmaceutical industry is difficult to ignore.

Regulators are actively investigating counterfeit and illegally distributed pharmaceutical products. In announcing the sentence, FDA’s Office of Criminal Investigations emphasized that administering counterfeit products puts consumers at serious risk and said FDA would continue pursuing those who endanger public health.